Analysis of tax risks associated with the possible qualification of the nature of the Group's business (federal pharmacy chain) as a "split" business scheme
Analysis of the possibility of redomiciliation of a business entity in the ATS
Restructuring of a large pharmaceutical group of companies
Confirmation of the validity of the application for VAT refund outside the three-year period
Confirmation of the absence of an unjustified tax benefit in the form of a surcharge on goods